Literature DB >> 15279561

Monoamine oxidases: certainties and uncertainties.

Keith F Tipton1, Sinead Boyce, Jeff O'Sullivan, Gavin P Davey, Joe Healy.   

Abstract

A great deal has been learned about the behaviour of monoamine oxidase in the 75 years since it was first discovered, but there is still a great deal left to understand. This review concentrates on the dynamic aspects of our knowledge of the interactions of MAO with substrates and inhibitors and how it may collaborate with other enzymes, with particular emphasis on aspects that remain to be clarified. Copyright 2004 Bentham Science Publishers Ltd.

Mesh：

Substances：

Year:  2004        PMID： 15279561     DOI： 10.2174/0929867043364810

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  37 in total

Review 1.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury.

Authors:  Nina Kaludercic; Andrea Carpi; Roberta Menabò; Fabio Di Lisa; Nazareno Paolocci
Journal:  Biochim Biophys Acta       Date:  2010-09-24

2.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

3.  Catalytic properties of monoamine oxidase from the lamprey Lampetrafluviatilis liver.

Authors:  O V Yagodina; I N Basova; A V Lapin
Journal:  Dokl Biochem Biophys       Date:  2006 Sep-Oct       Impact factor: 0.788

4.  Platelet monoamine oxidase-A activity and aging: effect of carnosine.

Authors:  S Banerjee; M K Poddar
Journal:  J Physiol Sci       Date:  2013-05-09       Impact factor: 2.781

5.  4-Organoseleno-Isoquinolines Selectively and Reversibly Inhibit the Cerebral Monoamine Oxidase B Activity.

Authors:  Tuane Bazanella Sampaio; Juliana Trevisan Da Rocha; Marina Prigol; Rogério Aquino Saraiva; Pablo Froner Nogara; André Luiz Agnes Stein; João Batista Teixeira da Rocha; Gilson Zeni; Cristina Wayne Nogueira
Journal:  J Mol Neurosci       Date:  2016-04-06       Impact factor: 3.444

Review 6.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.

Authors:  Irene Bolea; Alejandro Gella; Mercedes Unzeta
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

7.  Discovery and Optimization of Inhibitors of the Parkinson's Disease Associated Protein DJ-1.

Authors:  Shinya Tashiro; Jose M M Caaveiro; Makoto Nakakido; Aki Tanabe; Satoru Nagatoishi; Yasushi Tamura; Noriyuki Matsuda; Dali Liu; Quyen Q Hoang; Kouhei Tsumoto
Journal:  ACS Chem Biol       Date:  2018-08-15       Impact factor: 5.100

8.  Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment.

Authors:  Ravid Doron; Ziv Versano; Or Burstein; Motty Franko; Alon Shamir; Roni Toledano; Assaf Handelsman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2019-07-09       Impact factor: 3.444

9.  Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.

Authors:  Zhaofei Yang; Xuan Wang; Jian Yang; Min Sun; Yong Wang; Xiaomin Wang
Journal:  Neurotox Res       Date:  2016-12-15       Impact factor: 3.911

10.  Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.

Authors:  Peter J H Scott; Brian G Hockley; Hank F Kung; Rajesh Manchanda; Wei Zhang; Michael R Kilbourn
Journal:  Appl Radiat Isot       Date:  2008-09-07       Impact factor: 1.513
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.